Welcome to our dedicated page for Instil Bio news (Ticker: TIL), a resource for investors and traders seeking the latest updates and insights on Instil Bio stock.
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company whose news flow centers on the development of novel therapies, with a particular focus on its lead asset AXN-2510, a PD-L1xVEGF bispecific antibody in development for multiple solid tumors. Company press releases and related SEC filings provide regular updates on clinical progress, collaborations, and financial results.
News about Instil Bio frequently covers clinical trial milestones for AXN-2510/IMM2510, including Phase 1 monotherapy studies in relapsed or refractory solid tumors and data from Phase 1 and Phase 2 studies in non-small cell lung cancer (NSCLC) conducted by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. in China. These updates have included preliminary safety and efficacy data, such as objective response rates and partial response rates in squamous and non-squamous NSCLC, as well as safety profiles in front-line NSCLC when ’2510 is combined with chemotherapy.
Investors and observers can also find corporate and financial updates in Instil Bio’s news, including quarterly financial results, operating expense details, and explanations of non-GAAP financial measures. Announcements have highlighted research and development spending, general and administrative expenses, and restructuring and impairment charges, along with reconciliations of GAAP to non-GAAP net loss and net loss per share.
Additional news items describe collaborations and corporate developments, such as the relationship with ImmuneOnco around ’2510, the role of Axion Bio, Inc. as a wholly-owned subsidiary dedicated to AXN-2510, leadership appointments including a Chief Medical Officer and board additions, and participation in healthcare conferences and investor events focused on the PD-(L)1xVEGF bispecific antibody landscape.
By following Instil Bio news, readers can track ongoing disclosures about AXN-2510’s clinical development, evolving collaboration arrangements, and the company’s financial and strategic updates as it advances its clinical-stage pipeline.
Instil Bio (Nasdaq: TIL) announced promising results from genomic analyses of tumor-infiltrating lymphocyte (TIL) therapies for metastatic melanoma. An objective response rate (ORR) of 67% was observed in 14 out of 21 patients. Key findings correlate tumor response with TIL clonal expansion and specific T cell populations. The results, showcasing the analytical advances in TIL therapy, will be presented at the ASGCT Annual Meeting on May 18, 2022. The research aims to enhance TIL efficacy, providing insights into anti-cancer therapies.
Instil Bio (Nasdaq: TIL) reported its Q1 2022 financial results, highlighting a cash position of $61.5 million and marketable securities of $318 million. The company is focused on advancing its tumor infiltrating lymphocyte (TIL) therapies, with ongoing enrollment in the DELTA-1 trial targeting advanced melanoma, aiming for top-line data in 2023. Additionally, a Phase 1 study of ITIL-306 is set to start in Q2 2022. The cash runway is projected to extend into 2024, backed by significant preclinical data presentations scheduled for ASCO 2022.
Instil Bio initiated the DELTA-1 Phase 2 trial of ITIL-168 for advanced melanoma, receiving orphan drug and fast-track designations from the FDA. The company expanded its manufacturing in the UK and the California facility is expected to commence operations in H1 2022. Financially, as of December 31, 2021, Instil had $454.1 million in cash and equivalents. Their R&D expenses rose to $107.3 million for the year, reflecting a substantial increase from 2020. 2021 culminated in a net loss of $156.8 million, with significant operational developments expected in 2022.
Instil Bio (Nasdaq: TIL), a clinical-stage biopharmaceutical firm, will participate in the Cell Therapy Panel at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:10 a.m. ET. The panel discussion will focus on their tumor infiltrating lymphocyte (TIL) therapies aimed at treating patients with cancer. Interested parties can access a live webcast at this link, with an archived replay available for 90 days post-event. For more details, visit www.instilbio.com.
Instil Bio (NASDAQ: TIL) provided a corporate update and financial results for Q3 2021. Key highlights include the initiation of a Phase 2 trial (DELTA-1) for ITIL-168 in metastatic melanoma after receiving FDA IND clearance and Fast Track Designation. The company reported $20.4 million in cash and cash equivalents with $495 million in marketable securities as of September 30, 2021, enabling operations through 2023. Research and development expenses surged to $29.1 million for Q3 2021, compared to $4.9 million in 2020, reflecting ramped-up clinical efforts.
Instil Bio, Inc. (Nasdaq: TIL) announced the presentation of pre-clinical data for its CoStimulatory Antigen Receptor (CoStAR) platform at the SITC 2021. Key findings indicate that CoStAR significantly enhances the effector function of T cells when combined with tumor-reactive signals. Notably, the anti-FOLR1 CoStAR construct demonstrated over 40% transduction efficiency in primary ovarian cancer TILs. The company looks forward to initiating a Phase 1 study of ITIL-306 in early 2022, with the potential to reduce toxicity associated with high-dose IL-2.
Instil Bio, Inc. (Nasdaq: TIL) announced its participation in two investor conferences in November 2021. The Cowen 5th Annual IO Next Summit is scheduled for November 15, 2021, from 4:45 PM to 5:05 PM ET, with a live session link available. The Jefferies Global Healthcare Conference will be held on November 18, 2021, at 3:00 AM ET, also offering a live session link. An archived replay of both events will be accessible on the company's website for 90 days post-presentation. Instil is dedicated to developing TIL therapies targeting various cancers.
Instil Bio, Inc. (NASDAQ: TIL) presented a subset analysis of treatment outcomes for its TIL therapy at the ESMO Congress 2021. The analysis focused on 12 patients with checkpoint inhibitor-refractory advanced cutaneous melanoma. Among them, 58% achieved an objective response, with a median overall survival of 21.3 months, indicating the potential effectiveness of TIL therapy in difficult cases. The therapy demonstrated manageable side effects, primarily from the pre-treatment regimen. Instil aims to further explore TIL therapy in its upcoming Phase 2 DELTA-1 clinical trial.
Instil Bio (Nasdaq: TIL) has received FDA clearance for its DELTA-1 Phase 2 clinical trial of ITIL-168, aimed at treating patients with advanced melanoma. The trial will focus on patients who have relapsed after PD-1 inhibitors and will include expanded cohorts for those who faced toxicity or had unsatisfactory responses. Topline results are expected in 2023, with potential regulatory submissions for a biologics license application in the U.S. and a marketing authorization in Europe in 2024.
Instil Bio, Inc. (NASDAQ: TIL) announced its participation in two investor conferences this September. The first is the Morgan Stanley 19th Annual Global Healthcare Conference on September 9 at 2:00 p.m. ET, featuring a fireside chat. Following that, Instil will present at Baird’s 2021 Virtual Global Healthcare Conference on September 14 at 5:30 p.m. ET. Live webcasts of these events will be available on the company’s website, with archived recordings accessible after the events.
FAQ
What is the current stock price of Instil Bio (TIL)?
What is the market cap of Instil Bio (TIL)?
